Company news

Oruka Therapeutics, Inc. news in 2026

Oruka Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Oruka Therapeutics to Participate in Multiple Upcoming Conferences

November 3, 2026

Oruka Therapeutics Announces Positive Week 16 Results for ORKA-001 from the Ongoing EVERLAST-B Trial in Moderate-to-Severe Psoriasis

October 26, 2026

Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026

October 25, 2026

Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional Dosing

September 23, 2026

Oruka Therapeutics to Attend the 2026 Morgan Stanley Global Healthcare Conference

September 9, 2026

Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer

August 24, 2026

Oruka Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 10, 2026

Oruka Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference

May 28, 2026

Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 13, 2026

Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology

May 6, 2026

Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering

April 28, 2026

Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering

April 27, 2026

Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis

April 27, 2026

Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Trial on April 27, 2026

April 26, 2026

Oruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

March 12, 2026

Oruka Therapeutics to Participate in Multiple Upcoming Conferences

February 8, 2026

Oruka Therapeutics Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of EVERLAST-B Trial of ORKA-001

January 11, 2026

Oruka Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 6, 2026

Decks in 2026